Leukotriene B₄

Leukotriene B₄ (LTB₄) is a dihydroxy fatty acid derived from arachidonic acid through the 5-LO pathway.^1,2,3 It promotes a number of leukocyte functions including aggregation, stimulation of ion fluxes, enhancement of lysosomal enzyme release, superoxide anion production, chemotaxis, and chemokinesis. In subnanomolar ranges (3.9 x 10⁻¹⁰ M), LTB₄ causes chemotaxis and chemokinesis in human polymorphonuclear leukocytes.⁴ At higher concentrations, (1.0 x 10⁻⁷ M), LTB₄ leads to neutrophil aggregation and degranulation as well as superoxide anion production.^4,5

WARNING This product is not for human or veterinary use.

1. Rådmark, O., Malmsten, C., Samuelsson, B., et al. Leukotriene A: Stereochemistry and enzymatic conversion to leukotriene B. Biochem. Biophys. Res. Commun. 92(3), 954-961 (1980).

2. Ford-Hutchinson, A.W., Bray, M.A., Doig, M.V., et al. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286(5770), 264-265 (1980).

3. McGee, J., and Fitzpatrick, F. Enzymatic hydration of leukotriene A₄. Purification and characterization of a novel epoxide hydrolase from human erythrocytes. The Journal of Biological Chemisty 260(23), 12832-12837 (1985).

4. Ford-Hutchinson, A.W. Leukotriene B₄ in inflammation. Crit. Rev. Immunol. 10(1), 1-12 (1990).

5. McMillan, R.M., and Foster, S.J. Leukotriene B₄ and inflammatory disease. Agents Actions 24(1-2), 114-119 (1988).

Tufail, Y.Z., Guijas, C., Kummer, D.A., et al. Suppression of pain transmission and behavior by inhibition of peripheral diacylglycerol metabolism. Cell Chem. Bio. 33(1), 74-90.e19 (2025).

Wei, C., Xu, Y., Zheng, Y., et al. The LTB₄-BLT₁ axis attenuates influenza-induced lung inflammation by suppressing NLRP3 activation. Cell Death Discov. 11(1), 148 (2025).

Mihlan, M., Wissmann, S., Gavrilov, A., et al. Neutrophil trapping and nexocytosis, mast cell-mediated processes for inflammatory signal relay. Cell S0092-8674(24), 00774-00778 (2024).

Wu, Z., Xiao, H., Rao, D., et al. Analytical strategy for oxylipin annotation by combining chemical derivatization-based retention index algorithm and feature tandem mass spectrometric fragmentation as a biomarker discovery tool. Anal. Chem. 95(43), 15933-15942 (2023).

Pang, Y., Liu, X., Zhao, C., et al. LC-MS/MS-based arachidonic acid metabolomics in acute spinal cord injury reveals the upregulation of 5-LOX and COX-2 products. Free Radic. Biol. Med. 193(Pt 1), 363-372 (2022).

Archambault, A.-S., Brassard, J., Bernatchez, É., et al. Human and mouse eosinophils differ in their ability to biosynthesize eicosanoids, docosanoids, the endocannabinoid 2-arachidonoyl-glycerol and its congeners. Cells 11(1), 141 (2022).

Archambault, A.-S., Zaid, Y., Rakotoarivelo, V., et al. High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients. The FASEB Journal 35(6), e21666 (2021).

Roberts, L.M., Schwarz, B., Speranza, E., et al. Pulmonary infection induces persistent, pathogen-specific lipidomic changes influencing trained immunity. iScience 24(9), 103025 (2021).

Hartling, I., Cremonesi, A., Osuna, E., et al. Quantitative profiling of inflammatory and pro-resolving lipid mediators in human adolescents and mouse plasma using UHPLC-MS/MS. Clin. Chem. Lab. Med. 59(11), 1811-1823 (2021).

Archambault, A.-S., Zaid, Y., Rakotoarivelo, V., et al. Lipid storm within the lungs of severe COVID-19 patients: Extensive levels of cyclooxygenase and lipoxygenase-derived inflammatory metabolites. medRxiv (2020).

Brouwers, H., Jónasdóttir, H.S., Kuipers, M.E., et al. Anti-inflammatory and proresolving effects of the omega-6 polyunsaturated fatty acid adrenic acid. J. Immunol. 205(10), 2840-2849 (2020).

Meriwether, D., Sulaiman, D., Volpe, C., et al. Apolipoprotein A-I mimetics mitigate intestinal inflammation in COX2-dependent inflammatory bowel disease model. J. Clin. Invest. 130, 3670-3685 (2019).

Dalli, J., Colas, R.A., Walker, M.E., et al. Lipid Mediator Metabolomics via LC-MS/MS Profiling and Analysis. Clinical Metabolomics 59-72 (2018).

Sorgi, C.A., Peti, A.P.F., Petta, T., et al. Comprehensive high-resolution multiple-reaction monitoring mass spectrometry for targeted eicosanoid assays. Sci. Data 5, 180167 (2018).

Archambault, A.-S., Turcotte, C., Martin, C., et al. Comparison of eight 15-lipoxygenase (LO) inhibitors on the biosynthesis of 15-LO metabolites by human neutrophils and eosinophils. PLoS One 13(8), e0202424 (2018).

Tsuda, S., Shinohara, M., Oshita, T., et al. Novel mechanism of regulation of the 5-lipoxygenase/leukotriene B₄ pathway by high-density lipoprotein in macrophages. Sci. Rep. 7(1), 12989 (2017).

Ichiki, T., Koga, T., Okuno, T., et al. Modulation of leukotriene B₄ receptor 1 signaling by receptor for advanced glycation end products (RAGE). The FASEB Journal 30(5), 1811-1822 (2016).

Qi, H.-Y., Daniels, M.P., Liu, Y., et al. A cytosolic phospholipase A₂-initiated lipid mediator pathway induces autophagy in macrophages. J. Immunol. 187(10), 5286-5292 (2011).

Levy, B.D., De Sanctis, G.T., Devchand, P.R., et al. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A₄. Nat. Med. 8(9), 1018-1023 (2002).

Fulton, D., Falck, J.R., McGiff, J.C., et al. A method for the determination of 5,6-EET using the lactone as an intermediate in the formation of the diol. J. Lipid Res. 39(8), 1713-1721 (1998).

Chavis, C., Fraissinet, L., Chanez, P., et al. A method for the measurement of plasma hydroxyeicosatetraenoic acid levels. Anal. Biochem. 271(1), 105-108 (1999).